In vitro-in vivo extrapolation of transporter-mediated clearance in the liver and kidney

Drug Metabolism and Pharmacokinetics

Volumn 24, Issue 1, 2009, Pages 37-52

  Kusuhara, Hiroyuki ^a   Sugiyama, Yuichi ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

Hepatic elimination; Hepatocytes; In vitro in vivo extrapolation; Kidney slices; Tubular secretion

Indexed keywords

ATORVASTATIN; BOSENTAN; BREAST CANCER RESISTANCE PROTEIN; CARNITINE; CERIVASTATIN; DIGOXIN; EBASTINE; FAMOTIDINE; FEXOFENADINE; FUROSEMIDE; MEMBRANE PROTEIN; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; NATEGLINIDE; OCTAMER TRANSCRIPTION FACTOR; OLMESARTAN; ORGANIC ANION TRANSPORTER; ORGANIC CATION TRANSPORTER; OUABAIN; PITAVASTATIN; PRAVASTATIN; QUINIDINE; RANITIDINE; REPAGLINIDE; ROSUVASTATIN; TELMISARTAN; THIONEINE; UNINDEXED DRUG; VALSARTAN; VERAPAMIL;

BLOOD BRAIN BARRIER; DRUG BINDING SITE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG ELIMINATION; DRUG PROTEIN BINDING; HUMAN; IN VITRO STUDY; IN VIVO STUDY; KIDNEY CLEARANCE; KIDNEY EPITHELIUM; LIVER CLEARANCE; MOLECULAR CLONING; MOLECULAR MECHANICS; NONHUMAN; PROTEIN FAMILY; REVIEW;

EID: 66449128354     PISSN: 13474367     EISSN: 18800920     Source Type: Journal    
DOI: 10.2133/dmpk.24.37     Document Type: Review

References (113)

1. Maeda, K. and Sugiyama, Y.: Impact of genetic polymorphisms of transporters on the pharmacokinetic, pharmacodynamic and toxicological properties of anionic drugs. Drug Metab Pharmacokinet, 23, 223-235 (2008).
2. Giacomini, K. M. and Sugiyama, Y.: Membrane transporters and drug response. In L. L. Brunton, J. S. Lazo, K. L. Parker, L. S. Goodman and A. G. Gilman (ed.). The Pharmacological Basis of Therapeutics 11th edition, Goodman & Gilman's 205, pp41-70.
3. El-Sheikh, A. A., Masereeuw, R. and Russel, F. G.: Mechanisms of renal anionic drug transport. Eur. J. Pharmacol., 585, 245-255 (2008).
4. Masereeuw, R. and Russel, F. G.: Mechanisms and clinical implications of renal drug excretion. Drug Metab. Rev., 33, 299-351 (2001).
5. Shitara, Y., Sato, H. and Sugiyama, Y.: Evaluation of drug-drug interaction in the hepatobiliary and renal transport of drugs. Annu. Rev. Pharmacol. Toxicol., 45, 689-723 (2005).
6. Obach, R. S.: Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: An examination of in vitro half-life approach and nonspecific binding to microsomes. Drug Metab. Dispos., 27, 1350-1359 (1999).
7. Watanabe, T., Kusuhara, H., Maeda, K., et al.: Physiologically based pharmacokinetic modeling to predict transportermediated clearance and distribution of pravastatin in humans. J. Pharmacol. Exp. Ther., (in press).
8. Ueda, K., Kato, Y., Komatsu, K., et al.: Inhibition of biliary excretion of methotrexate by probenecid in rats: quantitative prediction of interaction from in vitro data. J. Pharmacol. Exp. Ther., 297, 1036-1043 (2001).
9. Kitamura, Y.,Hirouchi, M., Kusuhara, H., et al.: Increasing systemic exposure of methotrexate by active efflux mediated by multidrug resistance-associated protein 3 (Mrp3/Abcc3). J. Pharmacol. Exp. Ther., (2008).
10. Shitara, Y. and Sugiyama, Y.: Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions. Pharmacol. Ther., 112, 71-105 (2006).
11. Iwatsubo, T., Hirota, N., Ooie, T., et al.: Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data. Pharmacol. Ther., 73, 147-171 (1997).
12. Miyauchi, S., Sawada, Y., Iga, T., et al.: Comparison of the hepatic uptake clearances of fifteen drugs with a wide range of membrane permeabilities in isolated rat hepatocytes and perfused rat livers. Pharm Res, 10, 434-440 (1993).
13. Yamazaki, M., Akiyama, S., Ni'inuma, K., et al., Biliary excretion of pravastatin in rats: contribution of the excretion pathway mediated by canalicular multispecific organic anion transporter. Drug Metab. Dispos., 25, 1123-1129 (1997).
14. Liu, X., LeCluyse, E. L., Brouwer, K. R., et al., Use of Ca2+ modulation to evaluate biliary excretion in sandwich-cultured rat hepatocytes. J. Pharmacol. Exp. Ther., 289, 1592-1599 (1999).
15. Abe, K., Bridges, A. S., Yue, W., et al.: In vitro biliary clearance of angiotensin II receptor blockers and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in sandwich-cultured rat hepatocytes: comparison with in vivo biliary clearance. J. Pharmacol. Exp. Ther., 326, 983-990 (2008).
16. Fukuda, H., Ohashi, R., Tsuda-Tsukimoto, M., et al.] Effect of plasma protein binding on in vitro-in vivo correlation of biliary excretion of drugs evaluated by sandwich-cultured rat hepatocytes. Drug Metab. Dispos., 36, 1275-1282 (2008).
17. Reigner, B. G., Williams, P. E., Patel, I. H., et al.: An evaluation of the integration of pharmacokinetic and pharmacodynamic principles in clinical drug development. Experience within Hoffmann La Roche. Clin. Pharmacokinet., 33, 142-152 (1997).
18. Lin, J. H.: Species similarities and differences in pharmacokinetics. Drug Metab. Dispos., 23, 1008-1021 (1995).
19. Mahmood, I.: Interspecies scaling of renally secreted drugs. Life Sci., 63, 2365-2371 (1998).
20. Nozaki, Y., Kusuhara, H., Kondo, T., et al.: Characterization of the uptake of organic anion transporter (OAT) 1 and OAT3 substrates by human kidney slices. J. Pharmacol. Exp. Ther., 321, 362-369 (2007).
21. Nozaki, Y., Kusuhara, H., Kondo, T., et al.: Species difference in the inhibitory effect of nonsteroidal anti-inflammatory drugs on the uptake of methotrexate by human kidney slices. J. Pharmacol. Exp. Ther., 322, 1162-1170 (2007).
22. Hasegawa, M., Kusuhara, H., Sugiyama, D., et al.: Functional involvement of rat organic anion transporter 3 (rOat3; Slc22a8) in the renal uptake of organic anions. J. Pharmacol. Exp. Ther., 300, 746-753 (2002).
23. Hasegawa, M., Kusuhara, H., Endou, H., et al.: Contribution of organic anion transporters to the renal uptake of anionic compounds and nucleoside derivatives in rat. J. Pharmacol. Exp. Ther., 305, 1087-1097 (2003).
24. Venien, C., Aubry M., Crine P., et al.: Determination of brush border membrane vesicle orientation using monoclonal antibodies recognizing extracytoplasmic and cytoplasmic domains of neutral endopeptidase-24.11. Anal. Biochem., 174, 325-330 (1988).
25. Haase, W., Schafer, A., Murer, H., et al.: Studies on the orientation of brush-border membrane vesicles. Biochem. J., 172, 57-62 (1978).
26. Abe, T., Unno, M., Onogawa, T., et al.: LST-2, a human liver-specific organic anion transporter, determines methotrexate sensitivity in gastrointestinal cancers. Gastroenterology, 120, 1689-1699 (2001).
27. Hirano, M., Maeda, K., Shitara, Y., et al.: Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the hepatic uptake of pitavastatin in humans. J. Pharmacol. Exp. Ther., 311, 139-146 (2004).
28. Ishiguro, N., Maeda, K., Kishimoto, W., et al.: Predominant contribution of OATP1B3 to the hepatic uptake of telmisartan, an angiotensin II receptor antagonist, in humans. Drug Metab. Dispos., 34, 1109-1115 (2006).
29. Pasanen, M. K., Neuvonen, M., Neuvonen, P. J. et al.: SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid. Pharmacogenet. Genomics., 16, 873-879 (2006).
30. Niemi, M., Backman, J. T., Kajosaari, L. I., et al.: Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics. Clin. Pharmacol. Ther., 77, 468-478 (2005).
31. Kalliokoski, A., Neuvonen, M., Neuvonen, P. J., et al.: Different effects of SLCO1B1 polymorphism on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinide. J. Clin. Pharmacol., 48, 311-321 (2008).
32. Pasanen, M. K., Fredrikson, H., Neuvonen, P. J., et al.: Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin. Clin. Pharmacol. Ther., 82, 726-733 (2007).
33. Shitara, Y., Itoh, T., Sato. H., et al.: Inhibition of transportermediated hepatic uptake as a mechanism for drug-drug interaction between cerivastatin and cyclosporin A. J. Pharmacol. Exp. Ther., 304, 610-616 (2003).
34. Lau, Y. Y., Huang, Y., Frassetto, L., et al.: effect of OATP1B transporter inhibition on the pharmacokinetics of atorvastatin in healthy volunteers. Clin. Pharmacol. Ther., 81, 194-204 (2007).
35. Ieiri, I., Suwannakul, S., Maeda, K., et al.: SLCO1B1 (OATP1B1, an Uptake Transporter) and ABCG2 (BCRP, an Efflux Transporter) Variant Alleles and Pharmacokinetics of Pitavastatin in Healthy Volunteers. Clin. Pharmacol. Ther., 82, 541-547 (2007).
36. Nishizato, Y., Ieiri, I., Suzuki, H., et al.: Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics. Clin. Pharmacol. Ther., 73, 554-565 (2003).
37. Maeda, K., Ieiri, I., Yasuda, K., et al.: Effects of organic anion transporting polypeptide 1B1 haplotype on pharmacokinetics of pravastatin, valsartan, and temocapril. Clin. Pharmacol. Ther., 79, 427-439 (2006).
38. Link, E., Parish, S., Armitage, J., et al.: SLCO1B1 variants and statin-induced myopathy--a genomewide study. N. Engl. J. Med., 359, 789-799 (2008).
39. Niemi, M., Neuvonen, P. J., Hofmann, U., et al.: Acute effect of pravastatin on cholesterol synthesis are associated with SLCO1B1 (encoding OATP1B1) haplotype *17. Pharmacogenet. Genomics., 15, 303-309 (2005).
40. Takane, H., Miyata, M., Burioka, N., et al.: Pharmacogenetic determinants of variability in lipid-lowering response to pravastatin therapy. J. Hum. Genet., 51, 822-826 (2006).
41. Igel, M., Arnold, K. A., Niemi, M., et al.: Impact of the SLCO1B1 polymorphism on the pharmacokinetics and lipid-lowering efficacy of multiple-dose pravastatin. Clin. Pharmacol. Ther., 79, 419-426 (2006).
42. Ito, K., Suzuki, H., Horie, T., et al.: Apical/basolateral surface expression of drug transporters and its role in vectorial drug transport. Pharm. Res., 22, 1559-1577 (2005).
43. Shitara, Y., Horie, T. and Sugiyama, Y., Transporters as a determinant of drug clearance and tissue distribution. Eur. J. Pharm. Sci., 27, 425-446 (2006).
44. Suzuki, H. and Sugiyama, Y.: Excretion of GSSG and glutathione conjugates mediated by MRP1 and cMOAT/MRP2. Semin. Liver. Dis., 18, 359-376 (1998).
45. Ando, T., Kusuhara, H., Merino, G., et al.: Involvement of Breast Cancer Resistance Protein (ABCG2) in the Biliary Excretion Mechanism of Fluoroquinolones. Drug. Metab. Dispos., 35, 1873-1879 (2007).
46. Hirano, M., Maeda, K., Matsushima, S., et al.: Involvement of BCRP (ABCG2) in the biliary excretion of pitavastatin. Mol. Pharmacol., 68, 800-807 (2005).
47. Sasaki, M., Suzuki, H., Aoki, J., et al.: Prediction of in vivo biliary clearance from the in vitro transcellular transport of organic anions across a double-transfected Madin-Darby canine kidney II monolayer expressing both rat organic anion transporting polypeptide 4 and multidrug resistance associated protein 2. Mol. Pharmacol., 66, 450-459 (2004).
48. Sasaki, M., Suzuki, H., Ito, K., et al.: Transcellular transport of organic anions across a double-transfected Madin-Darby canine kidney II cell monolayer expressing both human organic anion-transporting polypeptide (OATP2/SLC21A6) and Multidrug resistance-associated protein 2 (MRP2/ABCC2). J. Biol. Chem., 277, 6497-6503 (2002).
49. Matsushima, S., Maeda, K., Kondo, C., et al.: Identification of the Hepatic Efflux Transporters of Organic Anions Using Double-Transfected Madin-Darby Canine Kidney II Cells Expressing Human Organic Anion-Transporting Polypeptide 1B1 (OATP1B1)/Multidrug Resistance-Associated Protein 2, OATP1B1/Multidrug Resistance 1, and OATP1B1/Breast Cancer Resistance Protein. J. Pharmacol. Exp. Ther., 314, 1059-1067 (2005).
50. Cui, Y., Konig, J. and Keppler, D.: Vectorial transport by double-transfected cells expressing the human uptake transporter SLC21A8 and the apical export pump ABCC2. Mol. Pharmacol., 60, 934-943 (2001).
51. Otsuka, M., Matsumoto, T., Morimoto, R., et al.: A human transporter protein that mediates the final excretion step for toxic organic cations. Proc. Natl. Acad. Sci. USA, 102, 17923-17928 (2005).
52. Shu, Y., Brown, C., Castro, R. A., et al.: Effect of genetic variation in the organic cation transporter 1, OCT1, on metformin pharmacokinetics. Clin. Pharmacol. Ther., 83, 273-80 (2008).
53. Zelcer, N., van de Wetering, K., Hillebrand, M., et al.: Mice lacking multidrug resistance protein 3 show altered morphine pharmacokinetics and morphine-6-glucuronide antinociception. Proc. Natl. Acad. Sci. USA, 102, 7274-7279 (2005).
54. -/- mice. J. Pharmacol. Exp. Ther., 319, 1485-1491 (2006).
55. Tian, X., Swift, B., Zamek-Gliszczynski, M. J., et al.: Impact of basolateral multidrug resistance-associated protein (Mrp) 3 and Mrp4 on the hepatobiliary disposition of fexofenadine in perfused mouse livers. Drug Metab. Dispos., 36, 911-915 (2008).
56. Motohashi, H., Sakurai, Y., Saito, H., et al.: Gene expression levels and immunolocalization of organic ion transporters in the human kidney. J. Am. Soc. Nephrol., 13, 866-874 (2002).
57. Mikkaichi, T., Suzuki, T., Onogawa, T., et al.: Isolation and characterization of a digoxin transporter and its rat homologue expressed in the kidney. Proc. Natl. Acad, Sci, USA, 101, 3569-3574 (2004).
58. Tahara, H., Kusuhara, H., Maeda, K., et al.: Inhibition of oat3-mediated renal uptake as a mechanism for drug-drug interaction between fexofenadine and probenecid. Drug Metab. Dispos., 34, 743-747 (2006).
59. Tahara, H., Kusuhara, H., Endou, H., et al.: A species difference in the transport activities of H2 receptor antagonists by rat and human renal organic anion and cation transporters. J. Pharmacol. Exp. Ther., 315, 337-345 (2005).
60. Eraly, S. A., Vallon, V., Vaughn, D. A., et al.: Decreased renal organic anion secretion and plasma accumulation of endogenous organic anions in OAT1 knock-out mice. J. Biol. Chem., 281, 5072-5083 (2006).
61. Vallon, V., Rieg, T., Ahn, S. Y., et al.: Overlapping in vitro and in vivo specificities of the organic anion transporters OAT1 and OAT3 for loop and thiazide diuretics. Am. J. Physiol. Renal. Physiol., 294, F867-873 (2008).
62. Vanwert, A. L., Srimaroeng, C. and Sweet, D. H.: Organic anion transporter 3 (oat3/slc22a8) interacts with carboxyfluoroquinolones, and deletion increases systemic exposure to ciprofloxacin. Mol. Pharmacol.,, 122-131 (2008).
63. Vanwert, A. L., Bailey, R. M. and Sweet, D. H.: Organic anion transporter 3 (Oat3/Slc22a8) knockout mice exhibit altered clearance and distribution of penicillin G. Am. J. Physiol. Renal. Physiol., 293, F1332-1341 (2007).
64. VanWert, A. L. and Sweet, D. H.: Impaired clearance of methotrexate in organic anion transporter 3 (Slc22a8) knockout mice: a gender specific impact of reduced folates. Pharm Res, 25, 453-462 (2008).
65. Uchino, H., Tamai, I., Yamashita, K., et al.: p-aminohippuric acid transport at renal apical membrane mediated by human inorganic phosphate transporter NPT1. Biochem. Biophys. Res. Commun., 270, 254-359 (2000).
66. Imaoka, T., Kusuhara, H., Adachi-Akahane, S., et al.: The renal-specific transporter mediates facilitative transport of organic anions at the brush border membrane of mouse renal tubules. J. Am. Soc. Nephrol., 15, 2012-2022 (2004).
67. Huls, M., Brown, C. D., Windass, A. S., et al.: The breast cancer resistance protein transporter ABCG2 is expressed in the human kidney proximal tubule apical membrane. Kidney. Int., 73, 220-225 (2008).
68. van Aubel, R. A., Smeets, P. H., Peters, J. G., et al.: The MRP4/ ABCC4 gene encodes a novel apical organic anion transporter in human kidney proximal tubules: putative efflux pump for urinary cAMP and cGMP. J. Am. Soc. Nephrol., 13, 595-603 (2002).
69. Schaub, T. P., Kartenbeck, J., Konig, J., et al.: Expression of the conjugate export pump encoded by the mrp2 gene in the apical membrane of kidney proximal tubules. J. Am. Soc. Nephrol., 8, 1213-1221 (1997).
70. Ci, L., Kusuhara, H., Adachi, M., et al.: Involvement of MRP4 (ABCC4) in the luminal efflux of ceftizoxime and cefazolin in the kidney. Mol. Pharmacol., 71, 1591-1597 (2007).
71. Hasegawa, M., Kusuhara, H., Adachi, M., et al.: Multidrug resistance-associated protein 4 is involved in the urinary excretion of hydrochlorothiazide and furosemide. J. Am. Soc. Nephrol., 18, 37-45 (2007).
72. Imaoka, T., Kusuhara, H., Adachi, M., et al.: Functional involvement of multidrug resistance-associated protein 4 (MRP4/ABCC4) in the renal elimination of the antiviral drugs adefovir and tenofovir. Mol. Pharmacol., 71, 619-627 (2007).
73. Ranganathan, P., Culverhouse, R., Marsh, S., et al.: Methotrexate (MTX) pathway gene polymorphisms and their effects on MTX toxicity in Caucasian and African American patients with rheumatoid arthritis. J. Rheumatol., 35, 572-579 (2008).
74. Rau, T., Erney, B., Gores, R., et al.: High-dose methotrexate in pediatric acute lymphoblastic leukemia: impact of ABCC2 polymorphisms on plasma concentrations. Clin. Pharmacol. Ther., 80, 468-476 (2006).
75. Koepsell, H., Lips, K. and Volk, C.: Polyspecific organic cation transporters: structure, function, physiological roles, and biopharmaceutical implications. Pharm. Res., 24, 1227-1251 (2007).
76. Takano, M., Inui, K., Okano, T., et al.: Carrier-mediated transport systems of tetraethylammonium in rat renal brush-border and basolateral membrane vesicles. Biochim. Biophys. Acta., 773, 113-124 (1984).
77. Tamai, I., Yabuuchi, H., Nezu, J., et al.: Cloning and characterization of a novel human pH-dependent organic cation transporter, OCTN1. FEBS Lett., 419, 107-111 (1997).
78. Ohashi, R., Tamai, I., Nezu, Ji J., et al.: Molecular and physiological evidence for multifunctionality of carnitine/organic cation transporter OCTN2. Mol. Pharmacol., 59, 358-366 (2001).
79. Masuda, S., Terada, T., Yonezawa, A., et al.: Identification and functional characterization of a new human kidney-specific H +/organic cation antiporter, kidney-specific multidrug and toxin extrusion 2. J. Am. Soc. Nephrol., 17, 2127-2135 (2006).
80. Tanihara, Y., Masuda, S., Sato, T., et al.: Substrate specificity of MATE1 and MATE2-K, human multidrug and toxin extrusions\H(+)-organic cation antiporters. Biochem. Pharmacol., 74, 359-371 (2007).
81. Schinkel, A. H.: The roles of P-glycoprotein and MRP1 in the blood-brain and blood-cerebrospinal fluid barriers. Adv. Exp. Med. Biol., 500, 365-372 (2001).
82. Scherrmann, J. M.: Expression and function of multidrug resistance transporters at the blood-brain barriers. Expert. Opin. Drug Metab. Toxicol., 1, 233-46 (2005).
83. Schinkel, A. H., Smit, J. J., van Tellingen, O., et al.: Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell, 77, 491-502 (1994).
84. Jonker, J. W., Wagenaar, E. van Deemter, L., et al.: Role of blood-brain barrier P-glycoprotein in limiting brain accumulation and sedative side-effects of asimadoline, a peripherally acting analgaesic drug. Br. J. Pharmacol., 127, 43-50 (1999).
85. Adachi, Y., Suzuki, H. and Sugiyama, Y.: Comparative studie on in vitro methods for evaluating in vivo function of MDR1 Pglycoprotein. Pharm. Res., 18, 1660-1668 (2001).
86. Yamazaki, M., Neway, W. E., Ohe, T., et al.: In vitro substrate identification studies for p-glycoprotein-mediated transport: species difference and predictability of in vivo results. J. Pharmacol. Exp. Ther., 296, 723-35 (2001).
87. Jonker, J. W., Buitelaar, M., Wagenaar, E., et al.: The breast cancer resistance protein protects against a major chlorophyllderived dietary phototoxin and protoporphyria. Proc. Natl. Acad. Sci. USA, 99, 15649-15654 (2002).
88. Leggas, M., Adachi, M., Scheffer, G. L., et al.: Mrp4 confers resistance to topotecan and protects the brain from chemotherapy. Mol. Cell. Biol., 24, 7612-7621 (2004).
89. Enokizono, J., Kusuhara, H. and Sugiyama, Y.: Effect of breast cancer resistance protein (Bcrp/Abcg2) on the disposition of phytoestrogens. Mol. Pharmacol., 72, 967-975 (2007).
90. Enokizono, J., Kusuhara, H., Ose, A., et al.: Quantitative investigation of the role of breast cancer resistance protein (Bcrp/ Abcg2) in limiting brain and testis penetration of xenobiotic compounds. Drug Metab. Dispos., 36, 995-1002 (2008).
91. Ose, A., Ito, M., Kusuhara, H., et al.: Limited brain distribution of Ro 64-0802, a pharmacologically active form of oseltamivir, by active efflux across the blood-brain barrier mediated by organic anion transporter 3 (Oat3/Slc22a8) and multidrug resistance-associated protein 4 (Mrp4/Abcc4). Drug Metab. Dispos., (2008).
92. Belinsky, M. G., Guo, P., Lee, K., et al.: Multidrug resistance protein 4 protects bone marrow, thymus, spleen, and intestine from nucleotide analogue-induced damage. Cancer Res., 67, 262-8 (2007).
93. -/- (triple-knockout) and wild-type mice. Mol. Cancer. Ther., 7, 2280-2287 (2008).
94. Elsinga, P. H., Hendrikse, N. H., Bart, J., et al.: PET Studies on P-glycoprotein function in the blood-brain barrier: how it affects uptake and binding of drugs within the CNS. Curr. Pharm. Des., 10, 1493-1503 (2004).
95. Lee, Y. J., Maeda, J., Kusuhara, H., et al.: In Vivo Evaluation of P-glycoprotein Function at the Blood-Brain Barrier in Nonhuman Primates Using [11C]Verapamil. J. Pharmacol. Exp. Ther., 316, 647-553 (2006).
96. Sasongko, L., Link, J. M., Muzi, M., et al.: Imaging Pglycoprotein transport activity at the human blood-brain barrier with positron emission tomography. Clin. Pharmacol. Ther., 77, 503-514 (2005).
97. Wang, D. S., Jonker, J. W., Kato, Y., et al.: Involvement of organic cation transporter 1 in hepatic and intestinal distribution of metformin. J. Pharmacol. Exp. Ther., 302, 510-515 (2002).
98. Wang, D. S., Kusuhara, H., Kato, Y., et al.: Involvement of organic cation transporter 1 in the lactic acidosis caused by metformin. Mol. Pharmacol., 63, 844-848 (2003).
99. Krishnamurthy, P., Schwab, M., Takenaka, K., et al.: Transporter-mediated protection against thiopurine-induced hematopoietic toxicity. Cancer. Res., 68, 4983-4989 (2008).
100. van Montfoort, J. E., Stieger, B., Meijer, D. K., et al.: Hepatic uptake of the magnetic resonance imaging contrast agent gadoxetate by the organic anion transporting polypeptide Oatp1. J. Pharmacol. Exp. Ther., 290, 153-157 (1999).
101. Ghibellini, G., Leslie, E. M., Pollack, G. M., et al.: Use of tc-99m mebrofenin as a clinical probe to assess altered hepatobiliary transport: integration of in vitro, pharmacokinetic modeling, and simulation studies. Pharm. Res., 25, 1851-1860 (2008).
102. Guhlmann, A., Krauss, K., Oberdorfer, F., et al.: Noninvasive assessment of hepatobiliary and renal elimination of cysteinyl leukotrienes by positron emission tomography. Hepatology, 21, 1568-1575 (1995).
103. Levchenko, A., Mehta, B. M., Lee, J. B., et al.: Evaluation of 11C-colchicine for PET imaging of multiple drug resistance. J. Nucl. Med., 41, 493-501 (2000).
104. Hendrikse, N. H., de Vries, E. G., Eriks-Fluks, L., et al.: A new in vivo method to study P-glycoprotein transport in tumors and the blood-brain barrier. Cancer Res., 59, 2411-2416 (1999).
105. Gangloff, A., Hsueh, W. A., Kesner, A. L., et al.: Estimation of paclitaxel biodistribution and uptake in human-derived xenografts in vivo with (18)F-fluoropaclitaxel. J. Nucl. Med., 46, 1866-71 (2005).
106. Hendrikse, N. H., Schinkel, A. H., de Vries, E. G., et al.: Complete in vivo reversal of P-glycoprotein pump function in the blood-brain barrier visualized with positron emission tomography. Br. J. Pharmacol., 124, 1413-8 (1998).
107. Elsinga, P. H., Hendrikse, N. H., Bart, J., et al.: Positron emission tomography studies on binding of central nervous system drugs and P-glycoprotein function in the rodent brain. Mol. Imaging. Biol., 7, 37-44 (2005).
108. Bart, J., Dijkers, E. C., Wegman, T. D., et al.: New positron emission tomography tracer [(11)C]carvedilol reveals Pglycoprotein modulation kinetics. Br. J. Pharmacol., 145, 1045-1051 (2005).
109. de Vries, E. F., Kortekaas, R., vanWaarde, A., et al.: Synthesis and evaluation of dopamine D3 receptor antagonist 11C-GR218231 as PET tracer for P-glycoprotein. J. Nucl. Med., 46, 1384-1392 (2005).
110. Ishiwata, K., Kawamura, K., Yanai, K., et al.: In vivo evaluation of P-glycoprotein modulation of 8 PET radioligands used clinically. J. Nucl. Med., 48, 81-87 (2007).
111. Piwnica-Worms, D., Chiu, M. L., Budding, M., et al.: Functional imaging of multidrug-resistant P-glycoprotein with an organotechnetium complex. Cancer. Res., 53, 977-84 (1993).
112. Hendrikse, N. H., Kuipers, F., Meijer, C., et al.: In vivo imaging of hepatobiliary transport function mediated by multidrug resistance associated protein and P-glycoprotein. Cancer Chemother Pharmacol., 54, 131-138 (2004).
113. Lorusso, V., Pascolo, L., Fernetti, C., et al.: In vitro and in vivo hepatic transport of the magnetic resonance imaging contrast agent B22956/1: role of MRP proteins. Biochem. Biophys. Res. Commun., 293, 100-105 (2002).